Medical Digest & Congress Report
By Medical Congress News
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Medical Congress News
Category: Health & Fitness
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 0
Reviews: 0
Episodes: 285
Description
The MedicalDigest.org / CongressReport.eu podcast covers the latest evidence based medical news from cardiology, hematology, oncology, diabetology, pulmonology, dermatology, urology and more. Made for healthcare professionals and researchers, we are an independent, open-access platform. CongressReport.eu portal enables HCPs to get acquainted with new clinical trial results, medical diagnostic and treatment guidelines. Our non-promotional website collects and stores the relevant scientific information, KOL insights, key lectures, poster presentations in a user-friendly format.
| Episode | Date |
|---|---|
|
HPV-associated head and neck cancers - report from Danube Symposium
|
May 15, 2024 |
|
Breakthroughs and challenges in the treatment of head and neck cancer - report from Danube Symposium
|
May 15, 2024 |
|
Featured Clinical Researches: acute coronary syndromes, atrial fibrillation related ablation procedures and aortic valve replacements - report from ACC2024
|
Apr 19, 2024 |
|
Late-Breaking Clinical Trials on Cholesterol Management, Hypertension and Exercise - report from ACC2024
|
Apr 19, 2024 |
|
Late Breaking Clinical Trial on ACC - report from ACC2024
|
Apr 19, 2024 |
|
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: the STEP-HFpEF and STEP-HFpEF DM randomised trials - report from ACC2024
|
Apr 18, 2024 |
|
Late-Breaking Clinical Trials V - report from ACC2024
|
Apr 17, 2024 |
|
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV - report from ACC2024
|
Apr 17, 2024 |
|
Late Breaking Clinical Trial on interventional cardiology - report from ACC2024
|
Apr 17, 2024 |
|
Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients - report from ACC2024
|
Apr 16, 2024 |
|
PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma? - report from ACC2024
|
Apr 16, 2024 |
|
ULTIMATE-DAPT: Most Patients With ACS Can Safely Stop Aspirin One Month Post PCI - report from ACC2024
|
Apr 12, 2024 |
|
EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death - report from ACC2024
|
Apr 12, 2024 |
|
Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial - report from ACC2024
|
Apr 12, 2024 |
|
Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials - report from ACC2024
|
Apr 11, 2024 |
|
Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock - report from ACC2024
|
Apr 11, 2024 |
|
Study Links E-Cigarette Use with Higher Risk of Heart Failure - report from ACC2024
|
Apr 11, 2024 |
|
Overall Survival Results of KEYNOTE-564
|
Apr 05, 2024 |
|
Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
|
Feb 12, 2024 |
|
Follicular Lymphoma highlights of the ASH 2023 Congress
|
Jan 26, 2024 |
|
Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia - report from ASH2023
|
Dec 21, 2023 |
|
Real-World Outcomes With Brexucabtagene Autoleucel - report from ASH2023
|
Dec 21, 2023 |
|
Ibrutinib-Venetoclax Combination Found Effective Against Mantle Cell Lymphoma - report from ASH2023
|
Dec 21, 2023 |
|
Present and future of Multiple Myeloma management - report from ASH2023
|
Dec 21, 2023 |
|
Highlights of the ASH 2023 Congress
|
Dec 21, 2023 |
|
Chronic Myeloid Leukemia: Novel Therapeutic Approaches - report from ASH2023
|
Dec 20, 2023 |
|
Acute myeloid leukemia highlights of ASH 2023 Congress
|
Dec 20, 2023 |
|
Chronic Myeloid Leukemia highlights of ASH 2023 Congress
|
Dec 20, 2023 |
|
Multiple Myeloma highlights of ASH 2023 Congress
|
Dec 20, 2023 |
|
Dramatically Worse Myeloma Outcomes in Real World vs. Trials - report from ASH2023
|
Dec 20, 2023 |
|
State of the art ALL treatement in 2023 - report from ASH2023
|
Dec 19, 2023 |
|
Acute myeloid leukemia highlights of the ASH 2023 Congress
|
Dec 19, 2023 |
|
Diagnostic and Therapeutic Novelties of Multiple Myeloma Management at ASH2023
|
Dec 19, 2023 |
|
Non-Hodgkin Lymphoma highlights of the ASH 2023 Congress - report from ASH2023
|
Dec 19, 2023 |
|
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone Outperforms VRd Alone for Multiple Myeloma - report from ASH2023
|
Dec 18, 2023 |
|
Revumenib Found Effective Against High-Risk KMT2Ar Acute Leukemia - report from ASH2023
|
Dec 18, 2023 |
|
Auto-HCT Improves PFS, Relapse Rates in Relapsed LBCL Subset During Complete Response - report from ASH2023
|
Dec 15, 2023 |
|
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL - report from ASH2023
|
Dec 15, 2023 |
|
Interpretable Artificial Intelligence Differentiates Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia - report from ASH2023
|
Dec 13, 2023 |
|
CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases - report from ASH2023
|
Dec 13, 2023 |
|
Medical Treatment of Renal Cell Carcinoma in 2023
|
Dec 04, 2023 |
|
Lung Cancer highlights of ESMO 2023 Congress
|
Nov 29, 2023 |
|
State of art lipid-lowering treatment in 2023
|
Nov 23, 2023 |
|
The importance of intensive lipid lowering in CV risk reduction: the role of early combination treatment
|
Nov 23, 2023 |
|
Lung cancer highlights of the ESMO 2023 Congress
|
Nov 10, 2023 |
|
Melanoma highlights of ESMO 2023 Congress
|
Nov 08, 2023 |
|
RCC highlights of ESMO 2023 Congress
|
Nov 08, 2023 |
|
Genitourinary cancer highlights of ESMO 2023 Congress
|
Nov 08, 2023 |
|
Breast Cancer highlights of the ESMO 2023 Congress
|
Nov 07, 2023 |
|
Treatment of mRCC in real world settings - report from ESMO2023
|
Nov 06, 2023 |
|
Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer - report from ESMO2023
|
Nov 06, 2023 |
|
Data Shows Survival Benefits with Tisotumab Vedotin in Cervical Cancer - report from ESMO2023
|
Nov 03, 2023 |
|
Late-breaking studies from ESMO 2023 - report from ESMO2023
|
Nov 03, 2023 |
|
KEYNOTE-942 mRNA-Based vaccine and novel techniques in the field of melanoma - report from ESMO2023
|
Nov 03, 2023 |
|
Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer - report from ESMO2023
|
Nov 02, 2023 |
|
Better use of existing drugs increases cervical cancer survival and reduces recurrence - report from ESMO2023
|
Nov 02, 2023 |
|
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer - report from ESMO2023
|
Nov 02, 2023 |
|
The CodeBreak 300 Trial in KRAS G12C-mutated mCRC - report from ESMO2023
|
Nov 01, 2023 |
|
Survival Improved With Nivolumab Plus Chemo in Urothelial Carcinoma - report from ESMO2023
|
Nov 01, 2023 |
|
Amivantamab Plus Chemotherapy as New First-Line Standard of Care in EGFR Exon 20 Insertion-Mutated Advanced NSCLC - report from ESMO2023
|
Nov 01, 2023 |
|
Selpercatinib improves outcomes in RET-mutant medullary thyroid cancer - report from ESMO2023
|
Oct 31, 2023 |
|
PSMAfore Study Unveils Game-Changing Results for Prostate Cancer Treatment - report from ESMO2023
|
Oct 30, 2023 |
|
Considerations of moderate asthma management - report from ERS2023
|
Oct 04, 2023 |
|
Heart Failure management in the post-COVID era - Lessons from the pandemic - report from ESC2023
|
Sep 13, 2023 |
|
Key points from the 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - report from ESC2023
|
Sep 13, 2023 |
|
Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19 - report from ESC2023
|
Sep 12, 2023 |
|
Burden of Cardiovascular Disease in the European Union - report from ESC2023
|
Sep 12, 2023 |
|
Highlights of ESC2023 Congress - Heart failure in focus - report from ESC2023
|
Sep 12, 2023 |
|
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the cardiologist's perspective - report from ESC2023
|
Sep 11, 2023 |
|
Main headlines of 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure - report from ESC2023
|
Sep 11, 2023 |
|
STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity - report from ESC2023
|
Sep 11, 2023 |
|
When real-world data meet real patients' needs: how to optimally treat patients with chronic coronary syndromes in 2023? - report from ESC2023
|
Sep 11, 2023 |
|
OCT vs. IVUS vs. angiography guidance: a real-time updated network meta-analysis - report from ESC2023
|
Sep 07, 2023 |
|
2023 ESC Guidelines for the Management of Endocarditis - report from ESC2023
|
Sep 07, 2023 |
|
DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure - report from ESC2023
|
Sep 07, 2023 |
|
HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency - report from ESC2023
|
Sep 07, 2023 |
|
BUDAPEST CRT Upgrade: Cardiac resynchronisation therapy upgrade in heart failure with right ventricular pacing - a multicentre, randomised, controlled trial - report from ESC2023
|
Sep 06, 2023 |
|
2023 ESC Guidelines for the Management of Acute Coronary Syndromes - report from ESC2023
|
Sep 06, 2023 |
|
2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the diabetologist's perspective - report from ESC2023
|
Sep 06, 2023 |
|
2023 ESC Guidelines for the Management of Cardiomyopathies - report from ESC2023
|
Sep 06, 2023 |
|
What is the optimal treatment of hypertension in diabetics? The ESH 2023 Hypertension Guidelines on Diabetes - report from ESH2023
|
Jul 18, 2023 |
|
Diabetes trials on SGLT2 and GLP1 and their effects on hypertension - report from ESH2023
|
Jul 18, 2023 |
|
The Rehabilitation of Beta-Blockers in the ESH Hypertension Guidelines - report from ESH2023
|
Jul 12, 2023 |
|
Hypertensive patients with diabetes: Are RAAS/Diuretic combinations the foundation of treatment? - report from ESH2023
|
Jul 12, 2023 |
|
Managing Hypertension in Real Practice: the New ESH2023 Hypertension Guidelines - report from ESH2023
|
Jul 12, 2023 |
|
Hyperuricemia in hypertensive patients - report from ESH2023
|
Jul 12, 2023 |
|
Hypertension in women - an underrecognized issue- report from ESH2023
|
Jul 10, 2023 |
|
What has changed in the new ESH Hypertension Guidelines? - report from ESH2023
|
Jul 10, 2023 |
|
When hypertension and dyslipidemia co-exist: How to decrease CV risk? - report from ESH2023
|
Jul 10, 2023 |
|
Hypertensive patients with heart disease: What should be the preferred combination? - report from ESH2023
|
Jul 10, 2023 |
|
Where is the role of triple combination in the management of hypertension? - report from ESH2023
|
Jul 07, 2023 |
|
The development of hypertension guidelines - report from ESH2023
|
Jul 07, 2023 |
|
”Ten Commandments” of Single Pill Combination Treatment in Hypertension - report from ESH2023
|
Jul 05, 2023 |
|
Beta-blockers in managing arterial hypertension - why, when and to whom? - report from ESH2023
|
Jul 05, 2023 |
|
Beyond the algorithm: What combination to choose in hypertension treatment? - report from ESH2023
|
Jul 05, 2023 |
|
Antihypertensive Drugs and Treatment Algorithms in the ESH2023 Hypertension Guidelines - report from ESH2023
|
Jul 05, 2023 |
|
Hypertension and kidney - the intricate relationship - report from ESH2023
|
Jul 05, 2023 |
|
Hot questions on blood pressure measurement in clinical practice - report from ESH2023
|
Jul 05, 2023 |
|
Significant LDL Cholesterol Reductions With ANGPTL3 siRNA in homozygous familial hypercholesterolaemia - report from EAS2023
|
Jun 19, 2023 |
|
HER2 treatment landscape 2023 - report from ESMO BC 2023
|
Jun 05, 2023 |
|
Do overweight and obesity confer an additional risk of CAD in patients with FH? - report from EAS2023
|
Jun 02, 2023 |
|
Objective assessement of skin disease severity with the help of AI
|
May 26, 2023 |
|
What's new in treatment of breast cancer? - Highlights of ESMO BC 2023
|
May 24, 2023 |
|
Hot topics in melanoma management - report from EADO2023
|
May 15, 2023 |
|
Functional Precision Medicine in Oncology - report from AACR2023
|
May 04, 2023 |
|
The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator - report from AACR2023
|
Apr 28, 2023 |
|
Current issues in the treatment of schizophrenia - report from EPA2023
|
Apr 12, 2023 |
|
Highlights of EPA 2023 - report from EPA2023
|
Apr 06, 2023 |
|
The Risk of Early Recurrent MI: What is the Role of Cholesterol Efflux and ApoA-I? - report from ACC2023
|
Apr 04, 2023 |
|
Bempedoic Acid Improves Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk - report from ACC2023
|
Mar 31, 2023 |
|
How to increase prescription of evidence-based therapies in adults with T2D and ASCVD? - The COORDINATE-Diabetes Study - report from ACC2023
|
Mar 29, 2023 |
|
The FREEDOM COVID Anticoagulation Strategy Randomized Trial - report from ACC2023
|
Mar 28, 2023 |
|
Minimally Invasive Versus Conventional Sternotomy For Mitral Valve Repair Surgery - UK Mini Mitral Trial - report from ACC2023
|
Mar 27, 2023 |
|
Can Patients with Hypertrophic Cardiomyopathy do Vigorous Exercise? - A Multinational Lifestyle And Exercise Study - report from ACC2023
|
Mar 22, 2023 |
|
Efficacy and Safety of Oral PCSK9 Inhibitor, MK-0616 in the Treatment of Hypercholesterolemia - report from ACC2023
|
Mar 21, 2023 |
|
Transcatheter Edge-to-Edge Repair of Functional Mitral Regurgitation in Heart Failure - The COAPT Trial - report from ACC2023
|
Mar 20, 2023 |
|
Elevated Lipoprotein(a) as a Risk Enhancing Factor for Atherosclerotic Cardiovascular Disease - report from ACC2023
|
Mar 16, 2023 |
|
Sotatercept in combination with background therapy for the treatment of Pulmonary Arterial Hypertension — STELLAR Trial - report from ACC2023
|
Mar 14, 2023 |
|
The Omega-3 Mystery: New Evidence Supports the Therapeutic Value of EPA - report from ACC2023
|
Mar 10, 2023 |
|
LMWH use in pregnancy: The Highlow and the ALPINE trial - report from ASH2022
|
Jan 10, 2023 |
|
Treatment options for early, HR+, HER2- Breast Cancer - report from SABCS2022
|
Jan 10, 2023 |
|
Post neoadjuvant therapy in Triple Negative Breast Cancer - report from SABCS2022
|
Jan 10, 2023 |
|
Highlights of the San Antonio Breast Cancer Symposium 2022 - report from SABCS2022
|
Dec 15, 2022 |
|
Targeting CV risk factors with GLP-1 RAs in people with obesity - report from EASD2022
|
Oct 18, 2022 |
|
Once weekly insulin: The ONWARDS 2 study - report from EASD2022
|
Oct 13, 2022 |
|
Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction - report from EASD2022
|
Oct 12, 2022 |
|
Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg - report from EASD2022
|
Oct 11, 2022 |
|
Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity - report from EASD2022
|
Oct 11, 2022 |
|
Let’s talk about CGM evidence: Using basal insulins in T1D in daily life and when exercising - report from EASD2022
|
Oct 05, 2022 |
|
Primary results of the phase 3 KEYNOTE-412 study - report from ESMO2022
|
Oct 05, 2022 |
|
Treatment with tumor-infiltrating lymphocytes versus ipilimumab for advanced melanoma - report from ESMO2022
|
Sep 29, 2022 |
|
Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity - report from EASD2022
|
Sep 28, 2022 |
|
The IPSOS trial - report from ESMO2022
|
Sep 23, 2022 |
|
Choices in asthma and COPD care: How to maximize outcomes for patients - report from ERS2022
|
Sep 19, 2022 |
|
A fresh look at pulmonary hypertension: practical takeaways for patient management - report from ESC2022
|
Sep 13, 2022 |
|
Influenza Vaccine Among Patients with Acute Coronary Syndromes: the VIP-ACS trial - report from ESC2022
|
Sep 12, 2022 |
|
Facing anticoagulation dilemmas in venous thromboembolism - report from ESC2022
|
Sep 12, 2022 |
|
The importance of optimal RAASi therapy in heart failure - report from ESC2022
|
Sep 08, 2022 |
|
Chronic coronary syndrome: re-thinking treatment management and outcome priorities - report from ESC2022
|
Sep 07, 2022 |
|
Dual antiplatelet therapy in practice - report from ESC2022
|
Sep 06, 2022 |
|
2022 ESC-ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - report from ESC2022
|
Sep 05, 2022 |
|
Guidelines in Practice: management of dyslipidaemias in the elderly - report from ESC2022
|
Sep 05, 2022 |
|
Guidelines in Practice: dual antiplatelet therapy (DAPT) - report from ESC2022
|
Sep 02, 2022 |
|
Getting to LDL-C goals and staying there long-term - report from ESC2022
|
Sep 01, 2022 |
|
Cardiorenal benefits of finerenone: protecting the heart and kidneys - report from ESC2022
|
Sep 01, 2022 |
|
The Journey to Address Unmet Needs Across all Haemophilia Indications - report from ISTH2022
|
Jul 29, 2022 |
|
Anticoagulant Advancements for VTE in Children - report from ISTH2022
|
Jul 29, 2022 |
|
Clinical Challenges in Patients with Venous Thromboembolism - report from ISTH2022
|
Jul 28, 2022 |
|
Good practice statements for antithrombotic therapy in the management of COVID-19 - report from ISTH2022
|
Jul 28, 2022 |
|
ISTH Proposal to Standardize Functional Assays in the Diagnosis of Heparin‐induced Thrombocytopenia - report from ISTH2022
|
Jul 27, 2022 |
|
Navigating the Joint Health Journey for Patients With Hemophilia - report from ISTH2022
|
Jul 27, 2022 |
|
Strategies for Assessing and Managing DOAC-Related Bleeding - report from ISTH2022
|
Jul 26, 2022 |
|
Approaches to Standardisation and Monitoring for Haemophilia Gene Therapy: Consistency, Considerations and Challenges - report from ISTH2022
|
Jul 26, 2022 |
|
Comparison between full dose and reduced dose enoxaparin in the management of cancer-associated venous thromboembolism - report from ISTH2022
|
Jul 25, 2022 |
|
Roles of FVIII in Endothelial Cell Biology: More than a Coagulation Factor? - report from ISTH2022
|
Jul 25, 2022 |
|
Diagnosis and management of primary aldosteronism - report from ESH2022
|
Jul 25, 2022 |
|
Adherence to antihypertensive treatment in patients with CKD: a barrier to optimal renoprotection - report from ISTH2022
|
Jul 22, 2022 |
|
Brain cancers and the risk of intracranial hemorrhage with DOACs versus Low Molecular Weight Heparin - report from ISTH2022
|
Jul 22, 2022 |
|
Special forms of hypertension, optomized prevention and hypertension epidemiology - report from ESH2022
|
Jul 22, 2022 |
|
“Ten months of needles, we’d better get it right!” - The Highlow Study - report from ISTH2022
|
Jul 21, 2022 |
|
ISTH Guidelines for Anticoagulation in COVID-19 - report from ISTH2022
|
Jul 21, 2022 |
|
The SAXOPHONE Study - report from ISTH2022
|
Jul 21, 2022 |
|
Current Guidelines on Perioperative Anticoagulation Management: DOACs - report from ISTH2022
|
Jul 20, 2022 |
|
Diagnosis and management of non-adherence in hypertension treatment - report from ESH2022
|
Jul 14, 2022 |
|
Implementation of the 2019 lipid guidelines: where are we now? - report from EAS2022
|
Jul 14, 2022 |
|
Nocturnal hypertension - report from ESH2022
|
Jul 12, 2022 |
|
Blood pressure management in older frail patients - report from ESH2022
|
Jul 11, 2022 |
|
Lifelong burden of hypertension - report from ESH2022
|
Jul 08, 2022 |
|
New pathogenic insights in chronic urticaria - report from EADV Symposium 2022
|
Jul 06, 2022 |
|
Novelties in the diagnosis and management of primary aldosteronism - report from ESH2022
|
Jun 21, 2022 |
|
Results from the phase 3 PARADIGM trial - report from ASCO2022
|
Jun 16, 2022 |
|
Detecting elevated lipoprotein(a) and addressing the ASCVD risks - report from EAS2022
|
Jun 16, 2022 |
|
Who needs injectable therapies for cholesterol lowering or statins and ezetimibe are enough for CVD prevention? - report from EAS2022
|
Jun 15, 2022 |
|
Pembrolizumab in CRC: What did we learn from the KEYNOTE-177 and the KEYNOTE-651 trials? - report from ASCO2022
|
Jun 15, 2022 |
|
The difference between the genetic and pharmacological inhibition of PCSK9 - report from EAS2022
|
Jun 10, 2022 |
|
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up - interview with Sibylle Loibl
|
Jun 10, 2022 |
|
Long-term efficacy and safety of ixekizumab - interview with Andrew Blauvelt
|
Jun 02, 2022 |
|
ESC/EAS joint session: What is new in secondary CV prevention?
|
Jun 02, 2022 |
|
ESC/EAS joint session: Advances in CV risk estimation with focus on dyslipidemia - report from EAS2022
|
May 31, 2022 |
|
Treatment options of chronic urticaria - report from EADV Symposium 2022
|
May 31, 2022 |
|
Novelties at the International Summit of Lung Cancer in Rome - report from ISLC2022 in Rome
|
May 30, 2022 |
|
Atrial fibrillation guidelines into clinical practice - report from EHRA2022
|
May 03, 2022 |
|
Recent developments of the conduction system pacing - report from EHRA2022
|
Apr 29, 2022 |
|
What do new guidelines tell us about conduction system pacing? - report from EHRA2022
|
Apr 28, 2022 |
|
Conduction system pacing: ready for prime time? - report from EHRA2022
|
Apr 28, 2022 |
|
Antithrombotic Approaches to Reduce the Risk of Secondary Event in CAD and PAD - report from ACC2022
|
Apr 22, 2022 |
|
Results from the EMPULSE Trial - report from ACC2022
|
Apr 20, 2022 |
|
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk - report from ACC2022
|
Apr 14, 2022 |
|
Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment - interview with Federico Cappuzzo
|
Apr 14, 2022 |
|
Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People - report from ACC2022
|
Apr 14, 2022 |
|
Protecting comorbid patients with atrial fibrillation from stroke - report from EHRA2022
|
Apr 11, 2022 |
|
How to reduce limb events including amputations in our patients? - report from ACC2022
|
Apr 08, 2022 |
|
Guidance in Heart Failure Care at ACC 2022 - report from ACC2022
|
Apr 08, 2022 |
|
EHRA scientific documents 2022 - report from EHRA2022
|
Apr 08, 2022 |
|
Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study - report from ACC2022
|
Apr 06, 2022 |
|
The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma - interview with David F. McDermott
|
Mar 10, 2022 |
|
How will the current therapeutic options change the treatment of RCC in the daily practice? - interview with Camillo Porta
|
Mar 10, 2022 |
|
Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma - interview with Stefan N. Symeonides
|
Mar 08, 2022 |
|
Treatment intensification in the treatment of prostate cancer - interview with Oliver Sartor
|
Mar 08, 2022 |
|
First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer - interview with Ken Kato
|
Mar 01, 2022 |
|
State of the art treatment of bladder cancer - interview with Matthew R. Zibelman
|
Mar 01, 2022 |
|
Treatment of iron deficiency in acute and chronic heart failure - interview with Piotr Ponikowski
|
Feb 11, 2022 |
|
Alcohol septal ablation in hypertrophic cardiomyopathy: past and future - interview with Hubert Seggewiss
|
Feb 09, 2022 |
|
The use of SGLT2 inhibitors in the prevention and treatment of heart failure - interview with Petar Seferovic
|
Feb 07, 2022 |
|
Direct myosin inhibitors in hypertrophic cardiomyopathy: a new era? - interview with Iacopo Olivotto
|
Feb 03, 2022 |
|
Diagnostic delay in pulmonary arterial hypertension - interview with Bodil Ivarsson and Barbro Kjellström
|
Jan 20, 2022 |
|
Clinical Impact of Liraglutide as a Treatment of Obesity - interview with Babak Dehestani
|
Jan 18, 2022 |
|
Association of GLP 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events - interview with Michael Camilleri
|
Jan 17, 2022 |
|
Novelties in the treatment of multiple myeloma 2021 - report from ASH2021
|
Dec 20, 2021 |
|
Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology - report from ASH2021
|
Dec 20, 2021 |
|
Novelties in the treatment of myelofibrosis and polycythemia vera 2021 - report from ASH2021
|
Dec 20, 2021 |
|
Highlights of the San Antonio Breast Cancer Symposium 2021 - report from SABCS2021
|
Dec 20, 2021 |
|
Antibody Response to Vaccination with Myeloid and Lymphoid Neoplasms - report from ASH2021
|
Dec 17, 2021 |
|
Final results of KEYNOTE-355 - report from SABCS2021
|
Dec 16, 2021 |
|
Results from the Randomized Phase 3 Transform Study - report from ASH2021
|
Dec 16, 2021 |
|
Novelties on the treatment of non-Hodgkin lymphoma - report from ASH2021
|
Dec 16, 2021 |
|
Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies - report from SABCS2021
|
Dec 16, 2021 |
|
PALLAS trial: Adjuvant palbociclib in HR+/HER2- early breast cancer - report from SABCS2021
|
Dec 15, 2021 |
|
The DESTINY-Breast03 trial - report from SABCS2021
|
Dec 14, 2021 |
|
Liraglutide for Weight Management in the Real World - interview with Roman Vangoitsenhoven
|
Dec 03, 2021 |
|
Clinical Impact of Liraglutide as a Treatment of Obesity - interview with Alexander Miras
|
Nov 17, 2021 |
|
The role of GLP-1 receptor agonists in weight reduction and cardiovascular risk reduction - interview with Michael Nauck
|
Nov 17, 2021 |
|
The role of SGLT2 inhibitors in the treatment of diabetes with cardiovascular disease - report from EASD2021
|
Oct 22, 2021 |
|
The current issues in Hypoglycaemia - report from EASD2021
|
Oct 19, 2021 |
|
Current guidelines on diabetes management - report from EASD2021
|
Oct 13, 2021 |
|
The MONALEESA-2 trial - report from ESMO2021
|
Sep 30, 2021 |
|
Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC) - report from ESMO2021
|
Sep 30, 2021 |
|
Should Cure Be A Reasonable Goal in aRCC? - report from ESMO2021
|
Sep 23, 2021 |
|
The Keynote 716 trial - report from ESMO2021
|
Sep 22, 2021 |
|
Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O? - report from ESMO2021
|
Sep 22, 2021 |
|
Highlights of the ESMO 2021 Congress - report from ESMO2021
|
Sep 21, 2021 |
|
Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB - report from ESMO2021
|
Sep 21, 2021 |
|
Metastases-free survival results from STAMPEDE - report from ESMO2021
|
Sep 21, 2021 |
|
Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB - report from ESMO2021
|
Sep 21, 2021 |
|
2021 ESC Guidelines - CVD Prevention - report from ESC2021
|
Sep 12, 2021 |
|
SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death - report from ESC2021
|
Sep 12, 2021 |
|
Antithrombin Deficiency Registry, an Update - report from ERS2021
|
Sep 10, 2021 |
|
ERS/EAACI statement on adherence to international adult asthma guidelines - report from ERS2021
|
Sep 09, 2021 |
|
Pulmonary hypertension and interstitial pulmonary fibrosis - report from ERS2021
|
Sep 09, 2021 |
|
The RIPCORD 2 trial - report from ESC2021
|
Sep 07, 2021 |
|
The STEP Study - report from ESC2021
|
Sep 07, 2021 |
|
2021 ESC Guidelines - Cardiac Pacing - report from ESC2021
|
Sep 07, 2021 |
|
ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation - report from ESC2021
|
Sep 07, 2021 |
|
TOMAHAWK: immediate angiography after out-of-hospital cardiac arrest - Valvular Heart Disease - report from ESC2021
|
Sep 07, 2021 |
|
2021 ESC Guidelines - Valvular Heart Disease - report from ESC2021
|
Sep 07, 2021 |
|
The APAF-CRT Trial - report from ESC2021
|
Sep 07, 2021 |
|
2021 ESC Guidelines - Cardiac Pacing - report from ESC2021
|
Sep 07, 2021 |
|
What is new about Angina? - report from ESC2021
|
Sep 07, 2021 |
|
LOOP Study: screening for AF with an implantable loop recorder to prevent stroke - report from ESC2021
|
Sep 03, 2021 |
|
2021 ESC Guidelines on Heart Failure - report from ESC2021
|
Sep 03, 2021 |
|
The SMART-MI Trial - report from ESC2021
|
Sep 03, 2021 |
|
Abelacimab for Prevention of Venous Thromboembolism - report from ISTH2021
|
Jul 26, 2021 |
|
State of the art treatment of breast cancer - report from ASCO2021
|
Jul 26, 2021 |
|
State of the art treatment of prostate cancer - report from ASCO2021
|
Jul 26, 2021 |
|
Clinical decision making in the treatment of melanoma - report from ASCO2021
|
Jul 26, 2021 |
|
Current state of immunotherapy options in the treatment of RCC - report from ASCO2021
|
Jul 26, 2021 |
|
Current state of immunotherapy options in the treatment of melanoma - report from ASCO2021
|
Jul 26, 2021 |
|
State of the art treatment of breast cancer - report from ASCO2021
|
Jul 26, 2021 |
|
The QUAZAR AML-001 Maintenance Trial - report from EHA 2021
|
Jul 26, 2021 |
|
Novelties in the treatment of Multiple Myeloma - report from EHA 2021
|
Jul 26, 2021 |
|
Harnessing the immune system in multiple myeloma: CAR T-cell therapy and bispecific antibodies - report from EHA 2021
|
Jul 26, 2021 |
|
Novelties in the treatment of follicular lymphoma - report from EHA 2021
|
Jul 26, 2021 |
|
Novelties on the treatment of Multiple Myeloma - report from EHA 2021
|
Jul 26, 2021 |
|
The evolution of hypertension management: The increasing role of triple therapy in clinical practice - report from ESH-ISH2021
|
Jul 26, 2021 |
|
20-years follow-up of ASCOT-legacy - report from ESH-ISH2021
|
Jul 26, 2021 |
|
ESH-ISH 2021 Late-Breakers Session - report from ESH-ISH2021
|
Jul 26, 2021 |
|
Important messages from EULAR2021: Impact of air pollution on RA flares, effect of COVID-19 on RA care, osteoporosis care of men - report from EULAR2021
|
Jul 23, 2021 |
|
Consequences of COVID-19 Outbreak on Mental Health - report from EPA2021
|
Jul 23, 2021 |
|
Meeting the challenges of schizophrenia care during the COVID-19 pandemic - report from EPA2021
|
Jul 23, 2021 |
|
Obstetric Complications: The Forgotten Risk Factor for Schizophrenia - report from EPA2021
|
Jul 23, 2021 |
|
Highlights of the EPA 2021 - report from EPA2021
|
Jul 23, 2021 |
|
Improving the management of hypertension: acting on key factors - report from ESH-ISH2021
|
Jul 23, 2021 |
|
The ISH 2020 global hypertension practice guidelines - report from ESH-ISH2021
|
Jul 23, 2021 |
|
Detailed summary of the Consensus Session of the SG-BCC 2021 - report from St. Gallen BCC 2021
|
Jul 23, 2021 |
|
PARADISE-MI: Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction - report from ACC2021
|
Jul 23, 2021 |
|
Hypertension Guidelines: Do They Vary Across the World as Much as My Blood Pressure Has Today - report from ACC2021
|
Jul 23, 2021 |
|
Care for patients with HER2-positive breast cancer - report from St. Gallen BCC 2021
|
Jul 22, 2021 |
|
Latest trends, developments in breast surgery - report from St. Gallen BCC 2021
|
Jul 22, 2021 |
|
Highlights of the 17th St. Gallen International Breast Cancer Conference - report from St. Gallen BCC 2021
|
Jul 22, 2021 |
|
De-escalation of early breast cancer therapy: Umberto Veronesi’s legacy - report from St. Gallen BCC 2021
|
Jul 21, 2021 |
|
The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer - report from St. Gallen BCC 2021
|
Jul 21, 2021 |
|
Current state of frontline immunotherapy options in the treatment of NSCLC - report from ASCO2021
|
Jul 19, 2021 |
|
Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma studies - report from EAU2021
|
Jul 16, 2021 |
|
Treatment of hematological malignancies in 2021 - report from EHA2021
|
Jul 05, 2021 |
|
Novelties in the treatment of chronic myeloid leukemia - report from EHA2021
|
Jul 05, 2021 |